Imperial College London   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (1902)

Organization Overview

First Clinical Trial
1997
NCT00010140
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Allergy and Clinical Immunology Section at NHLI,Imperial College London | Anuja Mitra | Chair of Nutrition. Imperial College London | Dr. Robin Carthart-Harris and Prof. David Nutt, Imperial College London, UK | Hammersmith Hospital, Imperial College London | Hammersmith Hospital NHS Trust | Hammersmith Hospitals NHS Trust | Health Protection Research Unit in HCAI & AMR | Homerton University Hospital NHS Foundation Trust | Imperial College | Imperial College Healthcare Trust, St Mary’s Hospital | Imperial College London | Imperial College London and Royal Brompton Hospital | Imperial College London, Chelsea and Westminster Hospital | Imperial College London Diabetes Centre | Imperial College London, UK | Imperial College London University | Imperial College Medical Center | Imperial College NHS Trust London | National Heart and Lung Institute, Imperial College | Royal Brompton & Harefield NHS Foundation Trust | Senior Lecturer Medical Oncology and Clinical Pharmacology | Sponsor Chief Investigator, Imperial College London | Thayyil, Sudhin | UCL University College, Denmark | UCL (University College London) | University College London, Barts Health NHS Foundation Trust | University College London Hospital NHS Foundation Trust | University College London (sponsor NSMP-ORANGE trial)